Prostate-specific Membrane Antigen: Alpha-labeled Radiopharmaceuticals.
PET Clin
; 19(3): 371-388, 2024 Jul.
Article
en En
| MEDLINE
| ID: mdl-38658230
ABSTRACT
Novel prostate-specific membrane antigen (PSMA) ligands labeled with α-emitting radionuclides are sparking a growing interest in prostate cancer treatment. These targeted alpha therapies (TATs) have attractive physical properties that deem them effective in progressive metastatic castrate-resistant prostate cancer (mCRPC). Among the PSMA TAT radiopharmaceuticals, [225Ac]Ac-PSMA has been used extensively on a compassionate basis and is currently undergoing phase I trials. Notably, TAT has the potential to improve quality of life and has favorable antitumor activity and outcomes in multiple scenarios other than in mCRPC. In addition, resistance mechanisms to TAT may be amenable to combination therapies.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Radiofármacos
/
Glutamato Carboxipeptidasa II
/
Antígenos de Superficie
Límite:
Humans
/
Male
Idioma:
En
Año:
2024
Tipo del documento:
Article